ClinicalTrials.gg
RecruitingNCT06842498Updated Aug 17, 2026

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

A Phase 2 interventional study of FG-3246 in Metastatic Castration-Resistant Prostate Cancer, sponsored by Kyntra Bio. Recruiting at 23 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Kyntra Bio · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 3,597 studies in Prostatic Neoplasms with a site in United States — 607 open to participants now, 975 under way, 101 of them phase 3. Prostatic Neoplasms · United States.

Planned enrollment
1,104th of 3,024
75 · median 48
Started
2026
with 175 others
Phase 2
1,063 of 3,597
145 open now
Primary completion
2028-03
later than 637 of 969 live
Registered
3,327th of 3,597
by date

Among the 3,597 studies in Prostatic Neoplasms with a site in United States, this one is the 1,104th largest by planned enrollment of the 3,024 interventional ones that give a count, is one of 176 that started in 2026, is one of 1,063 in phase 2, reaches primary completion later than 637 of the 969 other live ones, and was the 3,327th registered.

Prostatic Neoplasms

7,053 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

607 of the 3,597 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

602 more — sign in →

All 607 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,233 Prostatic Neoplasms studies recruiting now, 931 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,597 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC who have progressed following treatment with one prior second-generation androgen receptor signaling inhibitor (ARSI) in any setting and no prior taxane therapy in the mCRPC setting.

03

Conditions studied

  • Metastatic Castration-Resistant Prostate Cancer

Browse trials for

Keywords

  • FG-3246
  • FOR46
  • mCRPC
  • CRPC
  • CD46
  • Prostate cancer
  • Antibody-drug conjugate
  • Metastatic prostate cancer
  • FibroGen
  • ADC
  • Kyntra
  • Kyntra Bio
  • KYNB
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participant must have histological, and/or cytological confirmation of prostate adenocarcinoma on all prior tumor .
  • Participant with soft tissue disease and a safely accessible soft tissue tumor lesion(s) must agree to biopsy of a primary or lesion during screening. Alternatively, participant may provide a suitable archival biopsy of a primary or metastatic lesion.
  • Participant must have serum testosterone levels \<50 nanograms (ng)/deciliter (dL) during screening.
  • Participant is required to have progressed on no more than one prior treatment with a second generation ARSI (abiraterone acetate, enzalutamide, apalutamide, or darolutamide) initiated in either the castration-sensitive or castration-resistant setting.
  • Participant must have progressive mCRPC following last treatment at screening.
  • Participant must have ≥1 metastatic lesion that is present on baseline Computed Tomography (CT), Magnetic Resonance Imaging (MRI), or bone scan obtained ≤28 days prior to randomization.
  • Participant must have adequate organ function during screening.

Key Exclusion Criteria:

  • Participant has received previous treatment with a therapeutic targeting 6.
  • Participant has small cell neuroendocrine carcinoma (pure or mixed) on any prior histologic evaluation of primary or metastatic lesion.
  • Participant has progressed on more than one prior second-generation ARSI in any setting or has received more than two prior second-generation ARSIs in any setting.
  • Participants must not have received recent anticancer treatments before enrollment. Ongoing supportive or hormonal therapies are allowed if they were started well before randomization and are continued without change.
  • Participant has received any prior radiation therapy within 14 days prior to randomization.
  • Participant has a known actionable mutation or gene alteration, for example, BRCA1 mutation, for which approved therapies are available, for example, PARP inhibitors, unless these therapies are not appropriate for the participant as determined by the investigator or the participant refuses such therapy.
  • Participant has National Cancer institute (NCI) (CTCAE) ≥Grade 2 peripheral neuropathy at the time of screening from any etiology.
  • Participant has received any prior chemotherapy; however, one prior taxane-based chemotherapy in the castration-sensitive setting is allowed if completed >12 months before randomization.
  • Participant has known to the components of FG-3246 or its analogs or a history of allergic or anaphylactic reaction to human, humanized, or chimeric monoclonal antibodies.
  • Participant has diagnosis with any other in the past 5 years, except for adequately treated basal cell or squamous cell carcinoma of the skin.
  • Participant requires treatment with a strong cytochrome P450 3A4 () inhibitor or inducer drug that cannot be safely discontinued.

NOTE: Other protocol-defined inclusion/exclusion may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    FG-3246 1.8 mg/kg

    Participants will receive FG-3246 1.8 milligrams (mg)/kilogram (kg) administered via intravenous (IV) infusion on Day 1 of each 21-day treatment cycle (every 3 weeks \[Q3W\]) until radiographic progression, unacceptable safety and tolerability, participant or investigator decision to stop treatment, other withdrawal criteria are met, or sponsor decision to close the study.

    Drug: FG-3246

  • Experimental
    FG-3246 2.4 mg/kg

    Participants will receive FG-3246 2.4 mg/kg administered via IV infusion on Day 1 of each 21-day treatment cycle (Q3W) until radiographic progression, unacceptable safety and tolerability, participant or investigator decision to stop treatment, other withdrawal criteria are met, or sponsor decision to close the study.

    Drug: FG-3246

  • Experimental
    FG-3246 2.7 mg/kg

    Participants will receive FG-3246 2.7 mg/kg administered via IV infusion on Day 1 of each 21-day treatment cycle (Q3W) until radiographic progression, unacceptable safety and tolerability, participant or investigator decision to stop treatment, other withdrawal criteria are met, or sponsor decision to close the study.

    Drug: FG-3246

Interventions

  • FG-3246 will be administered per schedule specified in the arm description.

    Also known as: FOR46

06

What researchers measure

Primary outcomes

  1. Radiographic Progression-free Survival (rPFS) By Investigator Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) Criteria

    Time frame: Until radiographic progression is noted (up to approximately 25 months)

  2. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: From first dose until 28 days after last dose (up to approximately 25 months)

  3. Maximum Plasma Concentration (Cmax) of FG-3246, Total Anti-cluster of Differentiation 46 Antibody (CD46), and Free Monomethyl Auristatin E (MMAE)

    Time frame: Within each 21 day treatment cycle from Cycle 1 through 28 days post last dose (up to approximately 25 months)

Secondary outcomes

  1. rPFS Rate at 6 Months (rPFS6) Per RECIST v1.1 and PCWG3 Criteria

    Time frame: Month 6

  2. rPFS Rate at 12 Months (rPFS12) Per RECIST v1.1 and PCWG3 Criteria

    Time frame: Month 12

  3. Confirmed Objective Response Rate (ORR) Per RECIST v1.1 and PCWG3 Criteria

    Time frame: From first dose up to approximately 25 months

  4. Duration of Response (DoR) Per RECIST v1.1 and PCWG3 Criteria

    Time frame: From first dose up to approximately 25 months

  5. Confirmed PSA50 Response Rate: Percentage of Participants Achieving a Decline in Prostate-specific Antigen (PSA) ≥50% From Baseline

    Time frame: Up to approximately 25 months

  6. Confirmed PSA90 Response Rate: Percentage of Participants Achieving a Decline in PSA ≥90% From Baseline

    Time frame: Up to approximately 25 months

  7. Composite Response Rate (CRR) Per RECIST 1.1 and PCWG3 Criteria

    Time frame: Up to approximately 25 months

  8. PSA Progression-free Survival (PFS)

    Time frame: Up to approximately 25 months

  9. Disease Control Rate (DCR) per RECIST 1.1 and PCWG3 Criteria

    Time frame: Up to approximately 25 months

  10. Clinical Benefit Rate (CBR) per RECIST 1.1 and PCWG3 Criteria

    Time frame: Up to approximately 25 months

  11. Time to First Symptomatic Skeletal-related Event (SSRE)

    Time frame: Up to approximately 25 months

  12. Overall Survival (OS)

    Time frame: Until death or up to approximately 25 months

  13. Percentage of Participants Who Develop Anti-drug Antibodies (ADA) and Neutralizing Antibody (NAb) Against FG-3246

    Time frame: Within each 21 day treatment cycle from Cycle 1 through 28 days post last dose (up to approximately 25 months)

07

Study locations

23 of 23 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Mar 2028, 25 months after the start.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's planned 25 months is below that.

Counting every sponsor, half of 726 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2025
First posted
Feb 24, 2025
StartActual
Feb 22, 2026
Primary completionEst.
Mar 31, 2028
CompletionEst.
Mar 31, 2028
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06842498
Lead sponsor
Kyntra Bio
Responsible party
Sponsor
First posted
Feb 24, 2025
Start date
Feb 22, 2026
Primary completion
Mar 31, 2028 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Aug 17, 2026

Study contacts

Javier Moreno
Contact
jmoreno@kyntrabio.com
415-978-1466
Mairead Carney
Contact
mcarney@kyntrabio.com
415-978-1337

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD46 Antibody-drug Conjugate FOR46

Start the discussion